Paradox Immunotherapeutics
@ParadoxImmuno
Followers
30
Following
57
Media
1
Statuses
43
Reshaping the future of protein misfolding diseases.
Joined June 2021
RT @OBIOscience: Today is also a great opportunity to celebrate the incredible companies selected for our WiHI Seed Program 2023!. 👏🏽@AiVal….
0
3
0
RT @OBIOscience: @FilomenaTassi @Charmomof5 @cozen_oconnor @EYCanada @StemCellNetwork Shout-out to #OBIO’s 2023 #WiHI Seed cohort companies….
0
2
0
You heard it here first! Paradox is pleased to be participating in @MassBio 2024 Align Summit w/ insights by @McKinsey & @LocustWalkPtrs. Register for a day full of partnering opps. w/ investors, panels & presentations from early-stage #Biotech companies
0
0
1
RT @OBIOscience: Congratulations to Natalie Galant and the @ParadoxImmuno team for being #BIO2023 Emerging Start-Up Stadium winner. What a….
bio.news
Paradox's competitive edge in the field of protein misfolding research focuses on the development of monoclonal antibody (mAb) therapies.
0
1
0
RT @OBIOscience: 👏What an amazing accomplishment, @ParadoxImmuno! Last week, Paradox, an #OBIO member, was announced the winner of #BIO2023….
0
2
0
RT @OBIOscience: 👏@ParadoxImmuno is among the finalists at the Start-Up Stadium at #BIO2023. Here’s Natalie Galant, CEO and Co-founder of P….
0
3
0
Paradox is thrilled to announce that we have been selected as a finalist in this year's #BIO2023 Start-Up Stadium! Come see us in Boston on Wed June 7th to learn more about our R&D and recent milestones! #StandUpForScience
convention.bio.org
Start-Up Stadium provides start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the...
0
0
2
RT @vsanchorawala: Review article on renal amyloidosis by @ahavasi1 @BU_Amyloidosis .Amyloidosis and the Kidney: An Update .
pubmed.ncbi.nlm.nih.gov
Various types of systemic amyloidosis can wreak havoc on the architecture and functioning of the kidneys. Amyloidosis should be suspected in patients with worsening kidney function, proteinuria, and...
0
5
0
@ParadoxImmuno was proud to share its story with the viewers of @breakfasttv last week!.
ECHO is a national entrepreneurship training program supporting heart research commercialization. We're ensuring more life-changing technologies and innovations reach patients! #HeartMonth ♥️. WATCH Dr. @SororSharifpoor discuss ECHO on @breakfasttv 👀
0
0
1
Thank you for the continuous support, OCI! #womeninSTEM.
This weekend marked the #InternationalDayofWomenandGirlsinScience and we are recognizing @ParadoxImmuno! Natalie Galant is co-founder and CEO of Paradox, a biotech company that develops immunotherapies for diseases caused by protein misfolding.
0
0
0
RT @MMI_UofT: Thank you @ParadoxImmuno for your info session today! We really value your partnership and trust in us for #interns. It’s won….
0
1
0
RT @trogersresearch: ECHO is a national entrepreneurship training program supporting heart research commercialization. We're ensuring more….
0
6
0
RT @i_lousada: Calling next generation of amyloid researchers: there is much work to be done as presented by Per Westermark #ISA2018 https:….
0
2
0
0
2
0
RT @CanCGSF: CTA health participant @ParadoxImmuno is an orphan drug, preclinical-stage platform company dedicated to the creation of antib….
0
1
0
RT @CGCanSF: .@ParadoxImmuno , une entreprise participante à CTA Health, est une plateforme de médicaments orphelins, au stade préclinique,….
0
1
0
RT @JLABS: Kicking off our one-on-one video series, hear from Natalie Galant, CEO & co-founder of @ParadoxImmuno, on the rare disease start….
0
9
0
RT @JLABS: Your daily dose of inspiration delivered by the tremendous healthcare innovators at #JLABSDC! 👏🏻@AccGenetics @adipomics @algomet….
0
5
0
RT @JLABS: Have you met @ParadoxImmuno, Fibrocor Therapeutics or ArtisanBio yet? . Don’t miss your chance to get to know 3 of the newest #J….
0
4
0